Sat, Aug 30, 2014, 6:20 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Abbott Laboratories Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • Aok,
    I an sure generics will do fine but if you think the likes of MRK, ABT, GSK, BMY, PFE, ad nauseum will roll over and play dead without getting together or something else to continue making drugs/money you need some new tea leaves.
    c/Respect,
    O.
    When I get some >>div from gen.co.s they will be more attractive to me to have in a big way!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Aok,
      I an sure generics will do fine but if you think the likes of MRK, ABT, GSK, BMY, PFE, ad nauseum will roll over and play dead without getting together or something else to continue making drugs/money you need some new tea leaves.
      c/Respect,
      O.
      When I get some >>div from gen.co.s they will be more attractive to me to have in a big way!

      No, they won't. They will have an enduring institutional attraction because of their capitalization because the hedge funds need "safe stocks" which does not mean that they will grow. Just won't grow in this political environment.

      When I get really rich, I'll buy generics. I n the meanwhile, I will buy bluejeans.

      • 2 Replies to aok1903
      • No, they won't. They will have an enduring institutional attraction because of their capitalization because the MUTUAL funds need "safe stocks" which does not mean that they will grow. Just won't grow in this political environment.

        When I get really rich, I'll buy generics. In the meanwhile, I will buy bluejeans.

 
ABT
42.24-0.11(-0.26%)Aug 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.